NHC
AZN icon

Nicholas Hoffman & Company’s AstraZeneca AZN Stock Holding History

Nicholas Hoffman & Company’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
11,897
+17
+0.1% +$3.2K 0.05% 83
2026
Q1 		$2.34M Buy
11,880
+4
+0% +$771 0.05% 74
2025
Q4 		$2.18M Sell
11,876
-364
-3% -$63.8K 0.05% 78
2025
Q3 		$1.88M Sell
12,240
-192
-2% -$29.1K 0.05% 88
2025
Q2 		$1.74M Sell
12,432
-254
-2% -$35.6K 0.04% 85
2025
Q1 		$1.86M Buy
12,686
+11
+0.1% +$1.59K 0.07% 75
2024
Q4 		$1.66M Sell
12,675
-152
-1% -$21.3K 0.07% 82
2024
Q3 		$2M Buy
12,827
+5
+0% +$807 0.08% 70
2024
Q2 		$2M Sell
12,822
-181
-1% -$27.2K 0.09% 65
2024
Q1 		$1.76M Buy
13,003
+332
+3% +$44K 0.09% 73
2023
Q4 		$1.71M Buy
12,671
+238
+2% +$30.9K 0.1% 69
2023
Q3 		$1.68M Buy
12,433
+348
+3% +$47.5K 0.12% 69
2023
Q2 		$1.73M Buy
12,085
+100
+0.8% +$14.7K 0.07% 71
2023
Q1 		$1.66M Buy
11,985
+7
+0.1% +$942 0.15% 70
2022
Q4 		$1.62M Hold
11,978
– – 0.17% 69
2022
Q3 		$1.31M Sell
11,978
-25
-0.2% -$3.17K 0.06% 76
2022
Q2 		$1.59M Sell
12,003
-273
-2% -$35.8K 0.07% 65
2022
Q1 		$1.63M Buy
12,276
+7
+0.1% +$839 0.07% 64
2021
Q4 		$1.43M Hold
12,269
– – 0.05% 74
2021
Q3 		$1.47M Sell
12,269
-1,212
-9% -$141K 0.26% 68
2021
Q2 		$1.61M Hold
13,481
– – 0.29% 62
2021
Q1 		$1.34M Sell
13,481
-1,091
-7% -$110K 0.27% 70
2020
Q4 		$1.46M Buy
14,572
+500
+4% +$53K 0.34% 55
2020
Q3 		$1.54M Buy
14,072
+1,125
+9% +$125K 0.41% 45
2020
Q2 		$1.37M Buy
12,947
+82
+0.6% +$8.47K 0.39% 50
2020
Q1 		$1.15M Sell
12,865
-2,044
-14% -$192K 0.39% 57
2019
Q4 		$1.49M Hold
14,909
– – 0.41% 55
2019
Q3 		$1.33M Buy
14,909
+964
+7% +$83.6K 0.4% 56
2019
Q2 		$1.15M Buy
13,945
+1,375
+11% +$108K 0.36% 64
2019
Q1 		$1.02M Sell
12,570
-1,439
-10% -$113K 0.33% 73
2018
Q4 		$1.06M Sell
14,009
-261
-2% -$20.4K 0.37% 63
2018
Q3 		$1.13M Hold
14,270
– – 0.38% 61
2018
Q2 		$1M Sell
14,270
-335
-2% -$24.1K 0.37% 68
2018
Q1 		$1.02M Sell
14,605
-95
-0.6% -$6.58K 0.4% 63
2017
Q4 		$1.02M Hold
14,700
– – 0.4% 64
2017
Q3 		$996K Sell
14,700
-177
-1% -$11.2K 0.42% 65
2017
Q2 		$1.01M Buy
14,877
+645
+5% +$42.1K 0.46% 62
2017
Q1 		$886K Sell
14,232
-823
-5% -$47.9K 0.42% 66
2016
Q4 		$834K Buy
15,055
+631
+4% +$35.8K 0.42% 64
2016
Q3 		$948K Buy
14,424
+16
+0.1% +$1.05K 0.52% 53
2016
Q2 		$870K Buy
+14,408
New +$837K 0.5% 54

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Nicholas Hoffman & Company's AZN Position: Q2 2026 in Review

Nicholas Hoffman & Company increased its AstraZeneca (AZN) stake by 0.14% in Q2 2026, buying an estimated $3.2K and bringing the position to 11,897 shares worth $2.26M. The position accounts for 0.05% of the portfolio, ranked #83.

Nicholas Hoffman & Company first reported a position in AZN in Q2 2016 and has held it in 41 quarters since. The position peaked at $2.34M in Q1 2026. 906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Nicholas Hoffman & Company held 11,897 shares of AstraZeneca worth $2.26M as of Q2 2026.
  • Nicholas Hoffman & Company bought 17 AstraZeneca shares in Q2 2026, an estimated $3.2K.
  • AstraZeneca made up 0.05% of Nicholas Hoffman & Company's portfolio in Q2 2026, its #83 holding.
  • Nicholas Hoffman & Company first reported a position in AstraZeneca in Q2 2016 and has held it in 41 quarters since.
  • Nicholas Hoffman & Company's AstraZeneca position peaked at $2.34M in Q1 2026.
  • 906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Nicholas Hoffman & Company's 13F filing for Q2 2026, filed 4 Aug 2026.